KR102770110B1 - Cd38 항체 - Google Patents

Cd38 항체 Download PDF

Info

Publication number
KR102770110B1
KR102770110B1 KR1020207003078A KR20207003078A KR102770110B1 KR 102770110 B1 KR102770110 B1 KR 102770110B1 KR 1020207003078 A KR1020207003078 A KR 1020207003078A KR 20207003078 A KR20207003078 A KR 20207003078A KR 102770110 B1 KR102770110 B1 KR 102770110B1
Authority
KR
South Korea
Prior art keywords
antibody
antigen
delete delete
binding fragment
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207003078A
Other languages
English (en)
Korean (ko)
Other versions
KR20200036861A (ko
Inventor
앤 구비어
조세핀 살리무
비트리즈 고예네체아 코르조
파스칼 머치어스
케빈 모울더
니나 아이슬러
시몬 플로스토
헤만타 바루아
비안카 프린즈
Original Assignee
블랙 벨트 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 블랙 벨트 테라퓨틱스 리미티드 filed Critical 블랙 벨트 테라퓨틱스 리미티드
Publication of KR20200036861A publication Critical patent/KR20200036861A/ko
Application granted granted Critical
Publication of KR102770110B1 publication Critical patent/KR102770110B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207003078A 2017-08-16 2018-08-16 Cd38 항체 Active KR102770110B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762546336P 2017-08-16 2017-08-16
US62/546,336 2017-08-16
US201762582609P 2017-11-07 2017-11-07
US62/582,609 2017-11-07
PCT/EP2018/072272 WO2019034753A1 (en) 2017-08-16 2018-08-16 ANTIBODY CD38

Publications (2)

Publication Number Publication Date
KR20200036861A KR20200036861A (ko) 2020-04-07
KR102770110B1 true KR102770110B1 (ko) 2025-02-20

Family

ID=63259520

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003078A Active KR102770110B1 (ko) 2017-08-16 2018-08-16 Cd38 항체

Country Status (9)

Country Link
US (2) US11236173B2 (cg-RX-API-DMAC7.html)
EP (1) EP3668543A1 (cg-RX-API-DMAC7.html)
JP (1) JP7299873B2 (cg-RX-API-DMAC7.html)
KR (1) KR102770110B1 (cg-RX-API-DMAC7.html)
CN (1) CN111032086B (cg-RX-API-DMAC7.html)
AU (1) AU2018316522B2 (cg-RX-API-DMAC7.html)
CA (1) CA3072296A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202000484TA (cg-RX-API-DMAC7.html)
WO (1) WO2019034753A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
EP3993832A4 (en) * 2019-07-03 2023-10-18 Crystal Bioscience Inc. ANTI-CD38 ANTIBODIES AND METHOD OF USE THEREOF
US12181485B2 (en) 2020-09-10 2024-12-31 CASI Pharmaceuticals, Inc Methods of blood screening
CN112300281B (zh) * 2020-10-29 2021-06-11 杭州爱唯生命科技有限公司 含有nk细胞的药物组合物及其治疗癌症的用途
CN114437215B (zh) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 抗人cd38抗体及其制备方法和用途
WO2025213286A1 (zh) * 2024-04-07 2025-10-16 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种阻断单核巨噬细胞功能的cd38抑制剂在治疗itp中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU2011202520C1 (en) 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
AU2016228249A1 (en) 2006-09-26 2016-10-06 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2013209322A1 (en) 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
CN101605906A (zh) 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
CA2673870A1 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2342220B1 (en) 2008-10-06 2021-05-12 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
KR101545914B1 (ko) 2009-09-22 2015-08-20 프로바이오겐 아게 특수화된 글리칸 구조를 함유하는 분자의 생산 방법
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
BR112015021521A2 (pt) 2013-03-15 2017-10-10 Genentech Inc anticorpos anti-crth2 e métodos para seu uso
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
WO2016089862A1 (en) 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
CN113527495A (zh) 2015-04-08 2021-10-22 索伦托药业有限公司 与cd38结合的抗体治疗剂
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
EP3313441B1 (en) 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
MY206406A (en) 2015-10-02 2024-12-16 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
US12590171B2 (en) 2019-09-27 2026-03-31 Nanjing GenScript Biotech Co., Ltd. Anti-VHH domain antibodies and use thereof

Also Published As

Publication number Publication date
JP7299873B2 (ja) 2023-06-28
SG11202000484TA (en) 2020-02-27
EP3668543A1 (en) 2020-06-24
CA3072296A1 (en) 2019-02-21
US20220135697A1 (en) 2022-05-05
CN111032086A (zh) 2020-04-17
JP2020533965A (ja) 2020-11-26
US20200362050A1 (en) 2020-11-19
CN111032086B (zh) 2023-09-26
US12162949B2 (en) 2024-12-10
NZ761838A (en) 2025-03-28
AU2018316522B2 (en) 2025-02-20
US11236173B2 (en) 2022-02-01
KR20200036861A (ko) 2020-04-07
AU2018316522A1 (en) 2020-03-05
WO2019034753A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
US20240092928A1 (en) Cd38 modulating antibody
US20250367286A1 (en) Cd38 modulating antibody agents
US12162949B2 (en) CD38 antibody
US12304964B2 (en) CD38 modulating antibody
US11542338B2 (en) CD38 modulating antibody
KR102770104B1 (ko) Cd38 조정 항체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200131

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210810

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240105

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20240924

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241127

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20241211

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
PG1601 Publication of registration